Therapeutic molecules

A method for treating prostate cancer or a PSMA-expressing cancer comprising administering a therapeutically-effective amount of a binding molecule capable of binding human PSMA comprising a single human variable heavy chain domain (VH) antibody or a pharmaceutical composition comprising a binding molecule capable of binding human PSMA comprising a single human variable heavy chain domain (VH) antibody and a pharmaceutical carrier wherein said binding molecule comprises CDR1, CDR2 and CDR3 sequences selected from:

• a CDR1 sequence comprising SEQ ID NO. 81, a CDR2 sequence comprising SEQ ID NO. 82 and a CDR3 sequence comprising SEQ ID NO. 83, or
• a CDR1 sequence comprising SEQ ID NO. 85, a CDR2 sequence comprising SEQ ID NO. 86 and a CDR3 sequence comprising SEQ ID NO. 87, or
• a CDR1 sequence comprising SEQ ID NO. 89, a CDR2 sequence comprising SEQ ID NO. 90 and a CDR3 sequence comprising SEQ ID NO. 91, or
• a CDR1 sequence comprising SEQ ID NO. 93, a CDR2 sequence comprising SEQ ID NO. 94 and a CDR3 sequence comprising SEQ ID NO. 95, or
• a CDR1 sequence comprising SEQ ID NO. 97, a CDR2 sequence comprising SEQ ID NO. 98 and a CDR3 sequence comprising SEQ ID NO. 99, or
• a CDR1 sequence comprising SEQ ID NO. 101, a CDR2 sequence comprising SEQ ID NO. 102 and a CDR3 sequence comprising SEQ ID NO. 103, or
• a CDR1 sequence comprising SEQ ID NO. 105, a CDR2 sequence comprising SEQ ID NO. 106 and a CDR3 sequence comprising SEQ ID NO. 107, or
• a CDR1 sequence comprising SEQ ID NO. 109, a CDR2 sequence comprising SEQ ID NO. 110 and a CDR3 sequence comprising SEQ ID NO. 111, or
• a CDR1 sequence comprising SEQ ID NO. 113, a CDR2 sequence comprising SEQ ID NO. 114 and a CDR3 sequence comprising SEQ ID NO. 115, or
• a CDR1 sequence comprising SEQ ID NO. 1117, a CDR2 sequence comprising SEQ ID NO. 1118 and a CDR3 sequence comprising SEQ ID NO. 119, or
• a CDR1 sequence comprising SEQ ID NO. 121, a CDR2 sequence comprising SEQ ID NO. 122 and a CDR3 sequence comprising SEQ ID NO. 123, or
• a CDR1 sequence comprising SEQ ID NO. 125, a CDR2 sequence comprising SEQ ID NO. 126 and a CDR3 sequence comprising SEQ ID NO. 127, or
• a CDR1 sequence comprising SEQ ID NO. 129, a CDR2 sequence comprising SEQ ID NO. 130 and a CDR3 sequence comprising SEQ ID NO. 131, or
• a CDR1 sequence comprising SEQ ID NO. 133, a CDR2 sequence comprising SEQ ID NO. 134 and a CDR3 sequence comprising SEQ ID NO. 135, or
• a CDR1 sequence comprising SEQ ID NO. 137, a CDR2 sequence comprising SEQ ID NO. 138 and a CDR3 sequence comprising SEQ ID NO. 139, or
• a CDR1 sequence comprising SEQ ID NO. 141, a CDR2 sequence comprising SEQ ID NO. 142 and a CDR3 sequence comprising SEQ ID NO. 143, or
• a CDR1 sequence comprising SEQ ID NO. 145, a CDR2 sequence comprising SEQ ID NO. 146 and a CDR3 sequence comprising SEQ ID NO. 147, or
• a CDR1 sequence comprising SEQ ID NO. 149, a CDR2 sequence comprising SEQ ID NO. 150 and a CDR3 sequence comprising SEQ ID NO. 151, or
• a CDR1 sequence comprising SEQ ID NO. 153, a CDR2 sequence comprising SEQ ID NO. 154 and a CDR3 sequence comprising SEQ ID NO. 155, or
• a CDR1 sequence comprising SEQ ID NO. 157, a CDR2 sequence comprising SEQ ID NO. 158 and a CDR3 sequence comprising SEQ ID NO. 159, or
• a CDR1 sequence comprising SEQ ID NO. 161, a CDR2 sequence comprising SEQ ID NO. 162 and a CDR3 sequence comprising SEQ ID NO. 163, or
• a CDR1 sequence comprising SEQ ID NO. 165, a CDR2 sequence comprising SEQ ID NO. 166 and a CDR3 sequence comprising SEQ ID NO. 167, or
• a CDR1 sequence comprising SEQ ID NO. 169, a CDR2 sequence comprising SEQ ID NO. 170 and a CDR3 sequence comprising SEQ ID NO. 171, or
• a CDR1 sequence comprising SEQ ID NO. 173, a CDR2 sequence comprising SEQ ID NO. 174 and a CDR3 sequence comprising SEQ ID NO. 175, or
• a CDR1 sequence comprising SEQ ID NO. 177, a CDR2 sequence comprising SEQ ID NO. 178 and a CDR3 sequence comprising SEQ ID NO. 179.